255 related articles for article (PubMed ID: 33893148)
1. Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer.
Hirsch TZ; Pilet J; Morcrette G; Roehrig A; Monteiro BJE; Molina L; Bayard Q; Trépo E; Meunier L; Caruso S; Renault V; Deleuze JF; Fresneau B; Chardot C; Gonzales E; Jacquemin E; Guerin F; Fabre M; Aerts I; Taque S; Laithier V; Branchereau S; Guettier C; Brugières L; Rebouissou S; Letouzé E; Zucman-Rossi J
Cancer Discov; 2021 Oct; 11(10):2524-2543. PubMed ID: 33893148
[TBL] [Abstract][Full Text] [Related]
2. Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.
Pire A; Hirsch TZ; Morcrette G; Imbeaud S; Gupta B; Pilet J; Cornet M; Fabre M; Guettier C; Branchereau S; Brugières L; Guerin F; Laithier V; Coze C; Nagae G; Hiyama E; Laurent-Puig P; Rebouissou S; Sarnacki S; Chardot C; Capito C; Faure-Conter C; Aerts I; Taque S; Fresneau B; Zucman-Rossi J
Eur J Cancer; 2024 Mar; 200():113583. PubMed ID: 38330765
[TBL] [Abstract][Full Text] [Related]
3. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
Martinez-Becerra P; Vaquero J; Romero MR; Lozano E; Anadon C; Macias RI; Serrano MA; Grañé-Boladeras N; Muñoz-Bellvis L; Alvarez L; Sangro B; Pastor-Anglada M; Marin JJ
Mol Pharm; 2012 Jun; 9(6):1693-704. PubMed ID: 22524153
[TBL] [Abstract][Full Text] [Related]
4. Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Abril-Fornaguera J; Torrens L; Andreu-Oller C; Carrillo-Reixach J; Rialdi A; Balaseviciute U; Pinyol R; Montironi C; Haber PK; Del Río-Álvarez Á; Domingo-Sàbat M; Royo L; Akers NK; Willoughby CE; Peix J; Torres-Martin M; Puigvehi M; Cairo S; Childs M; Maibach R; Alaggio R; Czauderna P; Morland B; Losic B; Mazzaferro V; Guccione E; Sia D; Armengol C; Llovet JM
Mol Cancer Ther; 2023 Apr; 22(4):485-498. PubMed ID: 36780225
[TBL] [Abstract][Full Text] [Related]
5. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
6. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma.
Fuchs J; Wenderoth M; von Schweinitz D; Haindl J; Leuschner I
Cancer; 1998 Dec; 83(11):2400-7. PubMed ID: 9840541
[TBL] [Abstract][Full Text] [Related]
8. Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy.
Wu PV; Rangaswami A
Curr Oncol Rep; 2022 Sep; 24(9):1209-1218. PubMed ID: 35438389
[TBL] [Abstract][Full Text] [Related]
9. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT).
Hiyama E; Ueda Y; Onitake Y; Kurihara S; Watanabe K; Hishiki T; Tajiri T; Ida K; Yano M; Kondo S; Oue T;
Pediatr Surg Int; 2013 Oct; 29(10):1071-5. PubMed ID: 24026876
[TBL] [Abstract][Full Text] [Related]
10. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.
Casanova M; Massimino M; Ferrari A; Spreafico F; Piva L; Coppa J; Luksch R; Cefalo G; Terenziani M; Polastri D; Bellani FF; Mazzaferro V
Pediatr Hematol Oncol; 2005; 22(3):189-98. PubMed ID: 16020101
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines.
Takeuchi A; Kaneko S; Matsushita E; Urabe T; Shimoda A; Kobayashi K
J Gastroenterol; 1999 Jun; 34(3):351-8. PubMed ID: 10433011
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G; Maibach R; Shafford E; Brugieres L; Brock P; Morland B; de Camargo B; Zsiros J; Roebuck D; Zimmermann A; Aronson D; Childs M; Widing E; Laithier V; Plaschkes J; Pritchard J; Scopinaro M; MacKinlay G; Czauderna P
N Engl J Med; 2009 Oct; 361(17):1662-70. PubMed ID: 19846851
[TBL] [Abstract][Full Text] [Related]
13. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in hepatoblastoma.
Warmann SW; Fuchs J
Curr Pharm Biotechnol; 2007 Apr; 8(2):93-7. PubMed ID: 17430157
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 gene silencing in pediatric epithelial liver tumors.
Warmann SW; Frank H; Heitmann H; Ruck P; Herberts T; Seitz G; Fuchs J
J Surg Res; 2008 Jan; 144(1):43-8. PubMed ID: 17574594
[TBL] [Abstract][Full Text] [Related]
16. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.
Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF
Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL
Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740
[TBL] [Abstract][Full Text] [Related]
19. Enhancer-bound Nrf2 licenses HIF-1α transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells.
Jin X; Gong L; Peng Y; Li L; Liu G
Aging (Albany NY); 2020 Dec; 13(1):364-375. PubMed ID: 33290263
[TBL] [Abstract][Full Text] [Related]
20. Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma.
Zhang K; Shao CX; Zhu JD; Lv XL; Tu CY; Jiang C; Shang MJ
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32463473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
